Drugs / Sodium Tetradecyl Sulfate
Sodium Tetradecyl Sulfate
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | SOTRADECOL | — | 1946-08-13 | fda.gov ↗ |
Trials 7 · a red edge is where a trial was stopped
1945194619471948194919501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04655417 | Feb 2020 → Feb 2021 | — | Combined Military Hospital, Pakistan | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01408732 | Feb 2011 → Sep 2014 | hereditary hemorrhagic telangiectasia | University of Minnesota | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05597995 | Nov 2022 → May 2023 | epidermoid cysts | Goldman, Butterwick, Fitzpatrick and Groff | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06106971 | Jun 2018 → Jun 2025 | liver disorder, varicose disease | Kaohsiung Veterans General Hospital. | Unknown | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT02557542 | Oct 2015 → Mar 2021 | varicose disease | Imperial College London | Terminated | No outcome recorded |
| — | NCT06192472 | Apr 2013 → Jul 2015 | varicose disease | University of Surrey | Completed | No outcome recorded |
| — | NCT03363633 | Mar → Oct 2010 | vein disorder | Ellen Dillavou | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03311269 Comparator | Sep 2017 → May 2018 | venous insufficiency | Vascular Insights, LLC | Terminated | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02627846 Comparator | Jun 2015 → Aug 2018 | varicose disease | Hull University Teaching Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT02010437 Comparator | Jan 2014 → Jan 2015 | venous insufficiency | Hull University Teaching Hospitals NHS Trust | Withdrawn | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium tetradecyl sulfate | “3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose.” NCT01408732 ↗ |
| Known as | Fibro-vein injection | “3% sodium tetradecyl sulfate injection Name: Fibro-vein injection Manufacturer: STD Pharmaceutical Products Ltd.” NCT06106971 ↗ |
| Known as | Fibrovein | “The sclerosant will be Sodium Tetradecyl Sulphate (STS), marketed as Fibrovein.” NCT02627846 ↗ |
| Known as | Sodium Tetradecyl Sulphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06192472 ↗ |
| Known as | STD | “The sclerotherapy drug used will be Sodium Tetradecyl Sulphate, also known as STD and marketed as Fibrovein® (STD Pharmaceutical Products, Hereford, UK).” NCT02010437 ↗ |
| Known as | STS | “3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose.” NCT01408732 ↗1“Drug: Sodium Tetradecyl Sulphate (STS)” NCT02010437 ↗ |
| Route | Intravenous | “STS is currently approved by the U.S. Food and Drug Administration for intravenous use.” NCT03363633 ↗ |